Another $406 million could come in the form of clinical, regulatory and commercial milestones, and Enanta would be eligible for tiered, double-digit royalties and a U.S...and London-based GW Pharma plc, which is seeking a Nasdaq listing and a capital raise. (See BioWorld Today, March 11, 2013, March 12, 2013, and March 20, 2013.) In other financings news...Net proceeds are expected to support clinical trial costs and acquisition of manufacturing equipment, leasehold improvements and general corporate

Acasti Pharma Inc., of Laval, Quebec, a subsidiary of Neptune Technologies & Bioressources Inc., reported preliminary data from a randomized, open-label, dose-ranging, multicenter trial assessing the safety and efficacy of NKPL66, or CaPre, in mild-to-high hypertriglyceridemia...Nymox Pharmaceutical Corp., of Hasbrouck Heights, N.J., said the Phase II early stage prostate cancer trial with NX-1207 has reached the halfway point in patient recruitment...The NX03-0040 prostate cancer clinical study of

Dezima Pharma BV, of Naarden, the Netherlands, said it raised €14.2 million (US$18.6 million) for the clinical development of its cholesteryl ester transfer protein (CETP) inhibitor, DEZ-001 (previously TA-8995), and to develop additional earlier-stage dyslipidemia assets

As this money is dispensed through its clinical development programs, the company expects to receive £12 million in government R&D tax credits, bringing the total pot to £60 million...Pharma doesn't want more questions than answers, so you can't do development on a shoestring or cut corners...The total amount raised in the private placement is $7.9 million.

Clavis Pharma ASA, of Oslo, Norway, said it reached the enrollment target for its Phase III CLAVELA study investigating elacytarabine in patients with relapsed or refractory acute myeloid leukemia (AML...A further nine patients are expected to be enrolled at three oncological centers in the U.S. Based on the results, the company will implement a clinical study aimed at evaluating the effects of Reparixin, an inhibitor of the CXCR1 receptor activated by chemokine interleukin 8, in oral monotherapy

Noting a trend for pharma companies to engage in more collaborations and acquisitions in order to supplement their pipelines with new technology, Lammers said he could envision such an outcome for Mirna...Given the interest of big pharma in microRNA companies, including Mirna, I'm convinced if we have strong human proof-of-concept data in the clinic, most likely pharma will be interested in stepping up to the plate," Lammers said

The company was co-founded by former executives of MGI Pharma Inc., a Minneapolis-based firm that marketed several cancer drugs, including Dacogen (decitabine) for myelodysplastic syndromes, and was purchased in 2008 by Eisai Co...The company said it would allocate up to $40 million for the clinical development program for MM-398...The securities are subject to a four-month holding period.

1 million and will be used to fund R&D efforts, including clinical trials, and for general corporate purposes. (See BioWorld Today, Feb. 10, 2012...The specialty pharma firm also improved its interest terms.

In earlier stages, ChemoCentryx has CCX662, an independent candidate slated to start clinical trials for glioblastoma multiforme later this year, as well as five other wholly owned preclinical candidates

Once a common practice, early stage IPOs have gone the way of the dodo in recent years...Most investors expect clinical data in order to risk a substantial amount of money on a biotech venture...Proceeds will support clinical trials of Androxal and Proellex

Although the offering will allow the company to invest in its early stage candidates, "clearly, our main focus is on our lead program, SBC-102," he told BioWorld Today...support clinical development of chemotherapeutic gold nanoparticles targeting ovarian, lung and breast carcinoma...The company plans to use the proceeds to advance its hepatitis C virus program, earlier-stage pipeline opportunities and its screening platform.

Clavis Pharma ASA, of Oslo, Norway, reported interim efficacy data from a Phase II trial showing that elacytarabine in combination with idarubicin produced a complete remission rate in about 46 percent (12 of 26) of patients with early stage acute myeloid leukemia who had failed cytarabine-containing first-course chemotherapy

In April, Aptalis Pharma Inc. (formerly Axcan Holdings Inc.), based in Mont-Saint-Hilaire, Quebec, agreed to acquire the outstanding shares of Mpex and lead candidate, Aeroquin, an aerosol formulation of levofloxacin in Phase III trials for the treatment of pulmonary infections in patients with cystic fibrosis...The company is focusing on early stage assets developed at Mpex to treat multidrug-resistant Gram-negative infections

The company said proceeds from the IPO would see the company through 2013 and allow it to advance the TVI-Brain-1 clinical program, though additional financing would be needed to complete clinical trials of the compound...Just last week, year-old start-up Verastem Inc., of Cambridge, Mass., filed to raise $50 million to progress its lead cancer stem cell-targeting compound, though its technology is at a far earlier stage than that of TVAX. (See BioWorld Today, Nov. 4, 2011.) Through Oct. 10

True, there has been only one pricing since the spring – specialty pharma firm's Horizon Pharma Inc.'s $49.5 million offering in July – but the fact that a couple of other platform biotechs have jumped in the queue – Merrimack Pharmaceuticals Inc...and ChemoCentryx Inc. – is encouraging, though neither is as early stage as Verastem

About 100 patients with early stages of the disease will be enrolled and followed for more than six months, with assessments for safety, tolerability and efficacy...Tranzyme Pharma Inc., of Research Triangle Park, N.C., presented data from a Phase II trial of TZP-102, for gastroparesis in diabetes showing the drug significantly improved symptoms of the disease and was well tolerated with no effect on weight or glucose control

After reaching clinical proof of concept, it can seek the bigger markets...The specialty pharma and diagnostics company entered the deal with the Swiss firm in May. (See BioWorld Today, May 26, 2011.)

Souza would not comment on the details of that very early stage work, saying only that "it is too early to comment...A.P. Pharma Inc., of Redwood City, Calif., entered a definitive agreement with new and existing investors to raise $24 million in a private placement of common stock and warrants

Pharma Two B, of Rehovot, Israel, said it is planning a Phase II study of combination therapy P2B001, in development to treat the early stages of Parkinson's disease